Endocrine System Diseases  >>  Invokana (canagliflozin)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

15 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
CANTATA-M, NCT01081834 / 2009-015883-32: The (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Checkmark P3 data
Mar 2014 - Mar 2014: P3 data
Checkmark
Oct 2013 - Oct 2013: 
Checkmark EASD 2013
More
Completed
3
678
US, Europe, RoW
Canagliflozin, Placebo, Sitagliptin
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
08/11
03/12
NCT01106625 / 2009-016366-88: The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)

Checkmark P3 data
Mar 2014 - Mar 2014: P3 data
Checkmark
Oct 2013 - Oct 2013: 
Checkmark EASD 2013
More
Completed
3
469
US, Europe, RoW
Canagliflozin, Placebo, Metformin, Sulphonylruea
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
09/11
04/12
NCT01106677: The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Checkmark
Sep 2013 - Sep 2013: 
Checkmark ADA 2013
Jun 2013 - Jun 2013: ADA 2013
Checkmark P3 data
More
Completed
3
1284
US, Europe, RoW
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
10/11
05/12
NCT01106690 / 2009-018070-64: The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Checkmark
Feb 2014 - Feb 2014: 
Checkmark ADA 2013
Jun 2013 - Jun 2013: ADA 2013
Checkmark P3 data
More
Completed
3
344
US, Canada, Europe, RoW
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
11/11
07/12
NCT01106651 / 2010-018411-15: A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Checkmark
May 2013 - May 2013: 
Completed
3
716
US, Canada, Europe, RoW
Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
11/11
05/13
NCT00968812 / 2009-009320-36: CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Checkmark
Dec 2013 - Dec 2013: 
Checkmark ISPOR Eu 2013
Nov 2013 - Nov 2013: ISPOR Eu 2013
Checkmark ISPOR Eu 2013
More
Completed
3
1452
US, Canada, Europe, RoW
Glimepiride, sulfonylurea, Canagliflozin (JNJ-28431754), Metformin
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
12/11
01/13
NCT01064414 / 2009-017136-40: An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Checkmark EASD 2013
Jul 2013 - Jul 2013: EASD 2013
Checkmark ADA 2013
Jun 2013 - Jun 2013: ADA 2013
Checkmark
More
Completed
3
272
US, Canada, Europe, RoW
Canagliflozin, Placebo
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2, Renal Insufficiency
12/11
08/12
NCT01137812 / 2010-020053-14: The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Checkmark P3 data
Mar 2014 - Mar 2014: P3 data
Checkmark EASD 2013
Jul 2013 - Jul 2013: EASD 2013
Checkmark P3 data: CODHy 2012
More
Completed
3
756
US, Canada, Europe, RoW
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
03/12
03/12
NCT01413204: Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Completed
3
272
Japan
TA-7284 Low, TA-7284 High, Placebo
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
08/12
08/12
NCT01387737: Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Completed
3
1299
Japan
TA-7284-Low, TA-7284-High
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
11/12
12/12
NCT01381900: A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Completed
3
678
RoW
Placebo, Canagliflozin 100mg, Canagliflozin 300mg, Metformin, Sulphonylurea
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
11/12
11/12
NCT01809327 / 2011-000400-17: A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Completed
3
1186
US, Europe, RoW
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
12/14
12/14
NCT02354235: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Completed
3
138
Japan
Teneligliptin, Tenelia, MP-513, Canagliflozin, Canaglu, TA-7284, Placebo
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
01/16
01/16
NCT02354222: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Completed
3
154
Japan
Canagliflozin, Canaglu, TA-7284, Teneligliptin, Tenelia, MP-513, Placebo
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
02/16
02/16
CANVAS, NCT01032629 / 2009-012140-16: - CANagliflozin cardioVascular Assessment Study

Checkmark Results in patients with & without history of CV disease
Nov 2017 - Nov 2017: Results in patients with & without history of CV disease
Checkmark CANVAS data at ASN 2017
Nov 2017 - Nov 2017: CANVAS data at ASN 2017
Checkmark CANVAS program
More
Completed
3
4330
Canada, US, Europe, RoW
Placebo, Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
Janssen Research & Development, LLC, The George Institute for Global Health, Australia
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
02/17
02/17

Download Options